Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) have received an average rating of “Moderate Buy” from the fourteen brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $187.71.

Several research analysts have issued reports on JAZZ shares. Morgan Stanley reissued an “overweight” rating and issued a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. HC Wainwright raised their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their target price for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. Piper Sandler reissued an “overweight” rating and issued a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Finally, Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th.

Jazz Pharmaceuticals Trading Down 0.5 %

Jazz Pharmaceuticals stock opened at $139.51 on Wednesday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $148.06. The stock has a market capitalization of $8.47 billion, a PE ratio of 19.65, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The business’s fifty day moving average is $130.22 and its 200 day moving average is $121.18.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the sale, the chief executive officer now owns 425,525 shares of the company’s stock, valued at $52,522,550.75. The trade was a 0.35 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total value of $695,093.46. Following the completion of the sale, the chief accounting officer now directly owns 8,237 shares in the company, valued at approximately $1,189,587.54. The trade was a 36.88 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,736 shares of company stock valued at $4,022,825. 4.20% of the stock is owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. IFP Advisors Inc bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at approximately $25,000. Quadrant Capital Group LLC increased its position in shares of Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares during the last quarter. Elequin Capital LP increased its position in shares of Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 183 shares during the last quarter. CoreFirst Bank & Trust bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at approximately $28,000. Finally, Allianz SE bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at approximately $29,000. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.